Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

RegulatoryapprovedpTau217 Blood TestAD-DetectPositive

AI Analysis

Summary

Quest Diagnostics will offer the FDA-cleared Roche pTau217 blood test for assessing Alzheimer's disease pathology as part of its AD-Detect portfolio. The company is also launching a new multi-biomarker AD-Detect lab-developed test with a 10% indeterminate rate to provide more patients with actionable insights.

Outcome Details

FDA-cleared pTau217 blood test for Alzheimer's disease pathology assessment

Importance:6/10

Sentiment:

0.70

FDA clearancediagnostic testAlzheimer's diseaseblood testbiomarker

Related Companies

$DGX $RHHBY

Read the original article

Published by PR Newswire Biotech on August 24, 2026 11:24 AM

Read Original